MacroGenics (MGNX) said late Monday it will receive $24.5 million of regulatory milestone payments from Sanofi (SNY) following the US Food and Drug Administration's accelerated approval of Tzield to treat children aged eight to 17 with stage 3 type 1 diabetes.
The company remains eligible to receive up to $305 million in additional milestone payments, according to a statement.